Blockade of α4 Integrin Signaling Ameliorates the Metabolic Consequences of High-Fat Diet–Induced Obesity

Chloé C. Féra1,2, Jaap G. Neels,1 Christiane Kummer,1 Marina Slepak,1 Jerrold M. Olefsky,1 and Mark H. Ginsberg1

OBJECTIVE—Many prevalent diseases of advanced societies, such as obesity-induced type 2 diabetes, are linked to indolent mononuclear cell–dependent inflammation. We previously proposed that blockade of α4 integrin signaling can inhibit inflammation while limiting mechanism-based toxicities of loss of α4 function. Thus, we hypothesized that mice bearing an α4(Y991A) mutation, which blocks signaling, would be protected from development of high-fat diet–induced insulin resistance.

RESEARCH DESIGN AND METHODS—Six- to eight-week-old wild-type and α4(Y991A) C57Bl/6 male mice were placed on either a high-fat diet that derived 60% calories from lipids or a chow diet. Metabolic testing was performed after 16–22 weeks of diet.

RESULTS—α4(Y991A) mice were protected from development of high-fat diet–induced insulin resistance. This protection was conferred on wild-type mice by α4(Y991A) bone marrow transplant. In the reverse experiment, wild-type bone marrow renders high-fat diet–fed α4(Y991A) acceptor animals insulin resistant. Furthermore, fat-fed α4(Y991A) mice showed a dramatic reduction of monocyte/macrophages in adipose tissue. This reduction was due to reduced monocyte/macrophage migration rather than reduced monocyte chemotactic protein-1 production.

CONCLUSIONS—α4 integrins contribute to the development of HFD-induced insulin resistance by mediating the trafficking of monocytes into tissue; hence, blockade of α4 integrin signaling can prevent the development of obesity-induced insulin resistance. Diabetes 57:1842–1851, 2008

Obesity leads to insulin resistance that results in type 2 diabetes (1) and that contributes to hypertension and cardiovascular disease (2). Mononuclear cell–mediated inflammation in obese adipose tissue plays a pathogenetic role in insulin resistance (3,4). Thus, there is great interest in the possibility of using anti-inflammatory strategies to ameliorate obesity-induced insulin resistance.

Blockade of leukocyte adhesion is a proven therapeutic strategy for a wide variety of inflammatory diseases (5). In particular, inhibiting α4 integrins or their counter-receptors (vascular cell adhesion molecule-1 [VCAM-1] and mucosal adressin cell adhesion molecule-1 [MadCAM-1]) blocks inflammatory responses mediated by mononuclear leukocytes (6). α4 integrin antagonists are of proven benefit in several human inflammatory diseases (7,8). These antagonists, such as the monoclonal antibody natalizumab, block ligand binding function, thus producing a complete loss of α4 integrin function. Lack of α4 integrins is embryonic lethal and results in defective placentation, heart development, and hematopoiesis (9–11). Furthermore, natalizumab therapy has been associated with fatal progressive multifocal leukoencephalopathy in humans, possibly because of defective T-cell trafficking to the brain (12,13). Thus, currently available α4 integrin antagonists are of proven value in mononuclear cell–mediated diseases; however, complete loss of α4 integrin function is associated with developmental defects and abnormal hematopoiesis.

As noted above, whereas α4 integrin antagonists show promise for several autoimmune and inflammatory diseases, mechanism-based toxicities may limit their use, particularly in low-grade chronic inflammatory conditions, such as obesity-induced insulin resistance. We recently proposed an alternative strategy—blockade of α4 integrin signaling—to perturb functions involved in inflammation, while limiting mechanism-based adverse effects (14). α4 integrin signaling involves the binding of paxillin to the α4 integrin tail, and a point mutation (α4Y991A) that selectively blocks this interaction reduces α4-mediated leukocyte migration (15) and adhesion strengthening in flowing blood (16) while sparing α4-mediated static cell adhesion (17). Furthermore, mice bearing an α4(Y991A) mutation are viable and fertile and have intact lympho-hematopoiesis and humoral immune responses; however, they exhibit defective recruitment of mononuclear leukocytes in experimental inflammation (18). Here, we report that the α4(Y991A) mutation reduces mononuclear leukocyte infiltration of white adipose tissue (WAT) in high-fat diet–induced obese mice and hence reduce high-fat diet–induced insulin resistance. Thus, we establish that blocking α4 integrin signaling can ameliorate the metabolic consequences of high-fat diet–induced obesity.

RESEARCH DESIGN AND METHODS

Animals and animal care. The α4(Y991A) mice were previously described and have been backcrossed nine times onto the C57BL/6 background (18). We fed male mice (aged 6–8 weeks) either on high-fat diet, containing 60% fat by weight (D12492; Research Diets) or on chow diet (10% fat; D12450B; Research Diets) for 16–22 weeks. All experiments were approved by the University of California San Diego Institutional Animal Care and Use Committee.

Glucose and insulin tolerance tests. We carried out glucose tolerance tests (GTTs) and insulin tolerance tests (ITTs) as described previously (19) (see...
supplemental methods in the online appendix available at http://dx.doi.org/10.2337/db07-1751).

**Whole-blood and plasma measurements.** Total white blood cell number and differential counts were assessed by standard techniques (ACP Diagnostic Lab, University of California, San Diego). We measured plasma insulin by radioimmunoassay (Linco Research) and determined free fatty acids by enzymatic methods using an automated bichromatic radioimmunoassay (Linco Research). Plasma cholesterol and triglyceride levels were measured by enzymatic methods using an automated bichromatic analyzer (Abbott Diagnostics). All of these measurements were performed on 11 wild-type and 9 α4(Y991A) mice for high-fat diet and 6 wild-type and 5 α4(Y991A) mice for chow diet (Table 1).

**Histochemistry.** Adipose tissue was fixed overnight in 10% formaldehyde, dehydrated in ethanol bath, and paraffin-embedded. Sections were stained with hematoxylin-eosin (H-E) for observation of adipose tissue structure. Adipose tissue was fixed overnight in 10% formaldehyde, dehydrated in ethanol bath, and paraffin-embedded. Sections were stained with hematoxylin-eosin (H-E) for observation of adipose tissue structure.

**Isolation of stromal vascular cells.** Pancreata were isolated and fixed in 4% formalin overnight. Paraffin sections were generated with hematoxylin-eosin (H-E) for observation of adipose tissue structure. Adipose tissue was fixed overnight in 10% formaldehyde, dehydrated in ethanol bath, and paraffin-embedded. Sections were stained with hematoxylin-eosin (H-E) for observation of adipose tissue structure.

**Flow cytometry.** Cells were harvested from WAT, peripheral blood, and bone marrow and incubated in Fc blocker (rat anti-mouse CD16/32) for 20 min at room temperature. The cells were then incubated with fluorescein isothiocyanate (FITC)-Ly6G (1/200) and phycocerythrin (PE)-7/4 (1/500) (BD Biosciences/PharMingen, San Diego, CA). Negative control staining was performed with FITC-rat IgG2a and PE-rat IgG2a. Cell staining was analyzed with FACScan flow cytometer using CellQuest software (BD Biosciences Systems).

**Cell migration assay.** Cell migration was assayed in a modified Boyden chamber system using a 24-well transwell plate (8-μm pore size; Corning) coated with 5 μg/ml VCAM-1 (R&D Systems). Monocyte chemoattractant protein-1 (MCP-1) (R&D Systems) was added in the lower chamber at 1 nmol/l. Cells harvested from wild-type or α4(Y991A) bone marrow were grown for 5–7 days in the presence of granulocyte macrophage–colony-stimulating factor (5 μl of 0.1 mg/ml stock solution). Bone marrow–derived macrophages (2 × 10⁶) were kept in suspension in 1% serum containing medium for 1 h at room temperature. Cells were then added to the top chamber and incubated overnight at 37°C. Filters were fixed and stained with crystal violet, and migrated cells in the lower chamber were enumerated.

**RESULTS**

α4(Y991A) mutation is protective against the development of high-fat diet–induced glucose intolerance and insulin resistance. To investigate the role(s) of integrin α4 interaction with paxillin in α4-mediated functions in vivo, we previously generated and analyzed mice bearing a point mutation in the α4 integrin tail (Y991A) that inhibits paxillin binding with little detectable effect on the binding of other proteins (18). To examine the potential effect of this mutation on a model of human type 2 diabetes, these α4(Y991A) mice and wild-type controls were placed on a 60% fat diet for 16–22 weeks. On this diet, wild-type animals developed impaired glucose tolerance (Fig. 1A). In contrast, mice bearing the α4(Y991A) mutation were partially protected against high-fat diet–induced glucose intolerance (Fig. 1A; Supplemental Fig. 1A). The increased glucose tolerance in the high-fat diet–fed α4(Y991A) animals was not due to greater insulin release because these mice released significantly less insulin than high-fat diet–fed wild-type animals (P = 0.036) (Fig. 1B). The wild-type mice showed a greater increase in pancreatic β-cells than those bearing the α4(Y991A) mutation (Fig. 1C) in response to the high-fat diet. Because increased β-cells is an early manifestation of insulin resistance (22), these findings strongly suggested that the α4(Y991A) mutation helped preserve sensitivity to insulin in fat-fed animals. This idea was confirmed by the finding that the high-fat diet–fed mutant mice showed a much greater insulin-induced drop in blood glucose than the high-fat diet–fed wild-type mice (Fig. 1D). Thirty minutes after administration of 0.85 units/kg insulin, plasma glucose decreased by 43% in the mutant fat-fed animals compared with a 28% decline in wild-type animals. In contrast, the chow-fed animals of both genotypes exhibited a 37% decline at 30 min (0.75 units/kg insulin injected). At later time points, there was a statistically insignificant trend of greater insulin-induced drop in chow-fed α4(Y991A) animals ver-
FIG. 1. α4(Y991A) mutation protects mice against the development of high-fat diet–induced glucose intolerance and insulin resistance. A: In vivo glucose homeostasis was assessed by GTT in wild-type (●) and α4(Y991A) mice (□) on high-fat diet (plain symbols) and normal chow (dotted symbols). The results shown are means ± SE for each time point. B: Plasma insulin concentrations during GTT were collected. They are represented as total AUC, which was calculated using the trapezoidal method (see RESEARCH DESIGN AND METHODS for details). C: Size of pancreatic β-cell islets (right) in wild-type (closed) and α4(Y991A) (open) mice was measured. Representative H-E staining of wild-type and α4(Y991A) pancreas is also shown (left). Arrowheads indicate pancreatic islets. D: ITT was performed in wild-type (●) and α4(Y991A) mice (□) on high-fat diet (HFD; left) and normal chow (Chow; right). Plasma glucose was significantly higher in wild-type mice fed high-fat diet than in all other groups during both the GTTs and ITTs. No significant differences in plasma insulin during the GTT were found between the wild-type and α4(Y991A) mice on chow diet. Plasma insulin and percentage of pancreatic β-cell islets were significantly higher in the wild-type mice after high-fat diet. n values per group are indicated. *P < 0.05; **P < 0.01; ns, not significant.
sus wild type. Thus, the α4(Y991A) mutation protects against high-fat diet–induced insulin resistance. The α4(Y991A) mutation did not affect caloric intake or weight gain. Both wild-type and α4(Y991A) mice exhibited the same caloric intake on high-fat diet (Fig. 2A, left), which was about 1.5-fold higher than on chow diet (Fig. 2A, right). Consistent with similar caloric intake, no differences in weight gain were observed between wild-type and α4(Y991A) mice (Fig. 2B, left and right). Animals were weight matched before starting the 16 weeks of diet [average starting weight for high-fat diet, 27.8 ± 0.6 and 27.3 ± 1.0 g for wild type and α4(Y991A), respectively; for chow diet, 27.8 ± 1.3 and 28.8 ± 1.6 g for wild type and α4(Y991A), respectively]. Gross histological analysis of WAT isolated from high-fat diet–fed wild-type and α4(Y991A) mice showed no statistical difference in adipocyte size or number (Fig. 2C; Supplemental Fig. 1B).

Plasma levels of free fatty acids and triglycerides were similar between wild-type and α4(Y991A) mice on both diets (Table 1). Wild-type mice exhibited increased plasma cholesterol on high-fat diet (238.7 ± 10.5 mg/dl) in comparison with those on chow diet (132.2 ± 5.9 mg/dl). The α4(Y991A) mice on high-fat diet exhibited a statistically insignificant trend to a lesser rise in cholesterol (203.0 ± 27.9 vs. 130.0 ± 2.7 mg/dl, high-fat diet vs. chow diet), which may reflect a decrease in LDL levels. Plasma adiponectin concentrations decreased to similar levels in both high-fat–fed wild-type and α4(Y991A) mice. Plasma leptin and resistin levels increased after high-fat diet, but no differences were found between genotypes (Table 1). High-fat diet–fed α4(Y991A) mice exhibited similar plasma expression of proinflammatory cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and MCP-1, compared with wild-type mice (Table 1).

Bone marrow–derived cells are responsible for protection from high-fat diet–induced insulin resistance. Even though α4 integrin is not present at the surface of adipocytes (data not shown), it is widely expressed (23,24) and is particularly prominent in the functioning of mononuclear leukocytes. Moreover, bone marrow–derived mononuclear cells contribute to insulin resistance (3,4,25). To determine whether the protection against high-fat diet–induced insulin resistance in the α4(Y991A) mice is mediated through bone marrow–derived cells, we performed bone marrow transplantation (BMT) experiments. Six- to eight-week-old lethally irradiated (10 Gy) wild-type male mice received bone marrow cells from either wild-type or α4(Y991A) donor mice via tail vein injection. Recipient mice were allowed 4 weeks for recovery and reconstitution of the transplanted bone marrow and were then placed on high-fat diet for 16–22 weeks before metabolic experiments. Posttransplant chimerism was evaluated by PCR on both groups. No wild-type α4 was detected in blood collected from mice receiving bone marrow from α4(Y991A) mice [α4(Y991A)-BMT]. Mice transplanted with wild-type and α4 mutant [α4(Y991A)-BMT] bone marrow gained equal amounts of weight on high-fat diet compared with normal chow (data not shown). Levels of plasma fatty acids, cholesterol, triglycerides, adiponectin, and leptin were similar between genotypes (data not shown).

Wild-type mice that received α4(Y991A) bone marrow were partially protected against high-fat diet–induced glucose intolerance (Fig. 3A) and insulin resistance (Fig. 3B) compared with wild-type animals that received wild-type bone marrow. When animals were fed a normal diet, glucose tolerance was similar in mutant and wild-type transplanted mice (Fig. 3A), but there was a statistically insignificant trend toward increased insulin sensitivity in chow-fed α4(Y991A) compared with wild-type marrow recipients (Fig. 3C). In reverse BMT experiments, i.e., transplantation of wild-type bone marrow into lethally irradiated α4(Y991A) mice, no mutant allele was detected in α4(Y991A) animals receiving wild-type bone marrow, confirming complete reconstitution of wild-type bone marrow in these animals. Wild-type marrow made α4(Y991A) acceptor mice susceptible to glucose intolerance (Supplemental Fig. 2). Thus, bone marrow–derived cells are responsible for the observed protection of α4(Y991A) mice from high-fat diet–induced insulin resistance. The α4(Y991A) mutation leads to a decrease in adipose tissue monocyte/macrophages in high-fat diet–fed mice. The foregoing experiments showed that the effect of the α4(Y991A) mutation was manifest through bone marrow–derived cells. Among bone marrow–derived cells, α4 integrin is highly expressed on most mononuclear leukocytes (26). Monocyte/macrophages are bone marrow–derived mononuclear cells that mediate the inflammatory response to high-fat diet, and macrophages contribute to the pathogenesis of obesity-induced insulin resistance (25,27). We therefore used flow cytometry to quantify the presence of monocyte subpopulations, defined by the level of expression of surface markers 7/4 and Ly6-G (28) in the stromal vascular fraction (SVF) of WAT isolated from wild-type and α4(Y991A) mice on chow or high-fat diet. We used a combination of Ly-6G and 7/4 markers, described by Tsou et al. (28), which define a cell population uniformly positive for F4/80, CD11b, and CC chemokine receptor 2 for CCL2/MCP-1 (CCR2) and phenotypically identical to the inflammatory monocytes previously described (29–32).

The accumulation of macrophages, associated with obesity-induced insulin resistance, occurs predominantly in epididymal WAT (25,33); hence we studied WAT from this site. High-fat diet–fed α4(Y991A) mice exhibited a marked reduction in the number of monocytes (7/4dimLy-6Gneg) compared with high-fat–fed wild-type mice (0.8 ± 0.13 vs. 2.88 ± 0.49%) (Fig. 4A, top left panel) in WAT SVF. This phenomenon was also observed (Fig. 4A, bottom left panel) with 7/4dimLy-6Gneg cells (mixed monocyte/lymphocytes) (Y991A 3.77 ± 1.43% vs. wild type 7.6 ± 1.11%). In contrast, when fed a normal diet, wild-type and α4(Y991A) mice had similar percentages of both 7/4dimLy-6Gneg and 7/4dimLy-6Gmwg cells in their WAT SVF (Fig. 4A, right panels). These results were confirmed by the reduction in mRNA for F4/80, a macrophage marker, in WAT from fat-fed α4(Y991A) mice compared with wild-type mice (Supplemental Fig. 1C). Thus, the α4(Y991A) mutation leads to a reduction in monocyte/macrophage accumulation in the WAT SVF in response to high-fat diet.

WAT monocyte/macrophages derive in part from peripheral blood monocytes, which in turn are derived from the bone marrow. To investigate the cause of the reduced monocyte/macrophage accumulation in WAT of α4(Y991A) mice, we quantified monocyte subpopulations in the peripheral blood and in the bone marrow of wild-type and α4(Y991A) mice. In the high-fat diet–fed mice, there was a reduction in the percentage (1.4 ± 0.28 vs. 2.9 ± 0.38% for Y991A and wild type, respectively) and absolute number of monocytes in the peripheral blood of α4(Y991A) mice (Fig. 4A and B). In contrast, there was no significant difference in the
FIG. 2. Normal caloric intake, weight gain, and adipocyte size in α9(Y991A) mice compared with wild-type mice after high-fat diet. Calorie intake (A) and weight gain (B) were measured in wild type (○) and α9(Y991A) (●) mice on high-fat diet (HFD; left) and normal chow (chow; right). C: H-E staining of WAT isolated from wild type (WT) and α9(Y991A) (YA) mice was performed. No significant difference was observed between genotypes within diet. n values are indicated.
percentage of pure or mixed monocyte populations in the bone marrow of high-fat diet–fed wild-type and α4(Y991A) mice (Fig. 4A). Similarly, a slight monocytopenia was observed in the peripheral blood of normal chow–fed α4(Y991A) mice (1.71 ± 0.13 vs. 2.39 ± 0.12% for Y991A and wild type, respectively), and there was no significant difference in abundance of 7/4↑hiLy-6Gneg and 7/4↑dimLy-6Gneg cells in the bone marrow (Fig. 4). Taken together, these data suggest that the α4(Y991A) mutation does not impair monocyte development. Rather, they suggest that the mutation reduces mobilization of these cells. These data do not define the relative contributions of reduced egress from the bone marrow and entry into the adipose tissue in high-fat diet–fed mice in the observed reduced macrophage accumulation in α4(Y991A) WAT.

α4(Y991A) monocyte/macrophages exhibit reduced chemotaxis toward MCP-1. MCP-1 is an important monocyte chemoattractant and is particularly implicated in the mobilization of monocytes from the bone marrow and the infiltration of adipose tissue with monocyte/macrophages (34,35). Thus, we hypothesized that the decreased 7/4↑hiLy-6Gneg and 7/4↑dimLy-6Gneg cells in WAT of high-fat diet–fed α4(Y991A) mice could be due to impaired migration in response to this chemokine. α4(Y991A) bone marrow–derived macrophages showed reduced α4 integrin–dependent MCP-1–driven migration relative to wild-type cells (Fig. 5A). Thus, impaired α4 integrin–dependent monocyte/macrophage migration can account for the decreased number of monocyte/macrophages detected in WAT of fat-fed α4(Y991A) mice.

Chemokines, such as MCP-1, are produced by macrophages, endothelial cells, and adipocytes (4,36,37). Deficiency in MCP-1 production and/or secretion could also contribute to an impairment of monocyte/macrophages migration into adipose tissue (4). Circulating MCP-1 was increased approximately twofold after high-fat diet, but no significant difference was observed between genotypes (Table 1). The relative expression of MCP-1 was also evaluated in the WAT of α4(Y991A) and wild-type mice by RT-PCR (Fig. 5B). As expected from the circulating level of MCP-1, no difference was observed in MCP-1 mRNA expression in epididymal WAT between genotype in high-fat diet–fed mice (Fig. 5B). Thus, we ascribe the reduction in monocyte/macrophages in WAT in high-fat diet–fed mice to an impaired migratory response to MCP-1 rather than to reduced production of this chemokine.

The amelioration of insulin resistance in high-fat diet–fed α4(Y991A) mice appears to depend on reduction of monocyte/macrophages in WAT; these cells are the source of cytokines, such as TNF-α and IL-6. Abdominal adipose gene expression levels of TNF-α, IL-6, plasminogen activator inhibitor 1 (PAI-1), and leptin are positively linked with insulin resistance. Levels of proinflammatory cytokines TNF-α and IL6 were strikingly reduced (70 and 55%, respectively) in α4(Y991A) compared with wild-type WAT (Fig. 5C). In contrast, we observed similar levels for fat-derived peptides leptin and PAI-1 in wild-type and α4(Y991A) WAT. Thus, the reduction in monocyte/macrophages in WAT in high-fat diet–fed α4(Y991A) mice leads to reduced production of pro-inflammatory cytokines (TNF-α and IL-6) in WAT.

FIG. 3. Bone marrow cells from α4(Y991A) mice are sufficient for protection against high-fat diet–induced insulin resistance. GTTs (A) and ITTs (B and C) were performed in wild-type mice that received bone marrow from either wild-type (●) or α4(Y991A) (□) donors. Recipient animals were on high-fat diet (HFD; plain symbols) or normal chow (Chow; dotted symbols). The results shown are means ± SE for each time point. Plasma glucose was significantly lower in high-fat diet–fed wild-type mice that received α4(Y991A) bone marrow than in all other groups during both the GTTs and ITTs. n values per group are indicated. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.
FIG. 4. High-fat diet–fed α4(Y991A) mice exhibit a decreased number of adipose tissue and peripheral blood monocyte/macrophages. A: Stromal vascular cells of WAT, peripheral blood (blood) cells, and bone marrow (BM) cells were isolated from wild-type (■) and α4(Y991A) (□) mice were stained for 7/4 and Ly-6G surface markers. Mice were fed either high-fat diet (left) or normal chow (right). Quantification of 7/4hiLy-6Gneg (pure monocytes; top) and 7/4dimLy-6Gneg (mixed leukocyte population; bottom) cells was performed by flow cytometry. WAT of high-fat diet–fed α4(Y991A) mice contain a decreased number of pure monocyte (7/4hiLy-6Gneg) cells compared with wild type. The mixed population (7/4dimLy-6Gneg) also shows a decrease in the high-fat diet–fed α4(Y991A) WAT, although it does not reach significance. A slight monocytopenia (7/4hiLy-6Gneg) was measured in normal chow–fed α4(Y991A) mice, which was aggravated upon high-fat diet feeding. The decreased 7/4dimLy-6Gneg cell number was observed only in peripheral blood of high-fat diet–fed α4 mutant mice. No significant differences were observed in monocyte/macrophage numbers in the bone marrow in the two genotypes regardless of diet. Values are means ± SE. B: Quantification of monocytes from wild-type (■) and α4(Y991A) (□) hemograms is shown. Cell morphology was used to identify monocytes. Note that α4(Y991A) monocytopenia worsen when mice are fed a high-fat diet. Values are means ± SE. n values per group are indicated. *P < 0.05; **P < 0.01; ns, not significant.
FIG. 5. α4(Y991A) monocyte/macrophages show reduced migration in vitro in response to stimulation with MCP-1. A: Bone marrow–derived macrophages isolated from wild-type and α4(Y991A) mice were added to the top chamber of a VCAM-1–coated transwell. Chemoattractant, MCP-1 (1 nmol/l), was added in the lower chamber. Cells were allowed to migrate for 16 h. After fixation, cells were stained with crystal violet, and the total number of migrated cells (bottom chamber) was enumerated. B: Levels of MCP-1 mRNA were determined in vivo in epididymal WAT from wild-type and α4(Y991A) mice by using real-time RT-PCR. The data were normalized to the expression of V-ATPase. No significant difference was seen between genotypes. C: Levels of IL-6, PAI-1, TNF-α, and leptin mRNA were evaluated in vivo in WAT from wild-type and α4(Y991A) mice by real-time RT-PCR. Both TNF-α and IL-6 levels are decreased in α4(Y991A) compared with wild-type. Values are means ± SE (n = 14). **P < 0.01; ns, not significant.
α4 integrins are proven therapeutic targets in chronic inflammatory diseases, such as multiple sclerosis; however, complete blockade of α4 integrin function can result in defects in hematopoiesis, heart, and placentation (9,11,38,39) and is associated with progressive multifocal leukoencephalopathy (13). Chronic low-grade inflammation contributes to the development of insulin resistance (40), and the adipose tissue macrophage is a principal cell type responsible (27). Here, we report that mice bearing the α4(Y991A) mutation are protected from high-fat diet–induced glucose intolerance and insulin resistance. The mutation did not block development of monocytes in the bone marrow but impaired their migration in response to MCP-1, leading to a combination of reduced egress into the blood and diminished accumulation in adipose tissue. Reduction of α4(Y991A) monocyte/macrophages in WAT consequently diminished proinflammatory cytokine (IL-6 and TNF-α) production, which can explain the amelioration of insulin resistance in these mice. This is the first study showing a role for integrin signaling in the pathogenesis of the metabolic consequences of diet-induced obesity.

α4 integrins are important in the pathogenesis of high-fat diet–induced insulin resistance because they mediate the localization of monocyte/macrophages to adipose tissue. In particular, we found that a point mutation that impairs α4 integrin signaling led to markedly improved glucose tolerance and insulin sensitivity in high-fat diet–fed mice. The α4(Y991A) mice become obese on a high-fat diet, but they remained insulin-sensitive. This insulin-sensitive phenotype can be conferred by transplanting bone marrow from α4(Y991A) mice into irradiated wild-type host animals. In the reverse experiment, fat-fed α4(Y991A) mice receiving wild-type bone marrow were insulin resistant. Thus, bone marrow–derived cells are responsible for this protective effect, most likely by limiting accumulation of inflammatory adipose tissue macrophages. Recent studies have begun to classify macrophage subpopulations with differing roles in insulin resistance; future studies will be required to define effects of the α4(Y991A) mutation on these subpopulations (41–44). It is noteworthy that improvement of glucose tolerance in mutant mice fed a high-fat diet is not complete. This implies that other factors could contribute to glucose intolerance induced by high-fat diet. These results add insulin resistance/type 2 diabetes to diseases in which α4 integrins may serve as therapeutic targets.

Consistent with our results, MCP-1 deficiency or deletion of the MCP-1 receptor (CCR2) reduced monocyte egress from the bone marrow (28) and accumulation of macrophages in adipose tissue (4), and MCP-1 or CCR2 KO mice are partially protected from high-fat diet–induced insulin resistance (4,45). Thus, deletion of CCR2 or its main ligand leads to a similar phenotype as shown here for the α4(Y991A) mice. Furthermore, we demonstrated a defect in CCR2-driven chemotaxis in α4(Y991A) monocytes. These relationships suggest that CCR2-mediated monocyte recruitment is linked to the binding of paxillin to the α4 integrin cytoplasmic domain.

The phenotypes observed in the α4(Y991A) and α4(Y991A)-BMT animals are remarkably similar to those observed in mice deficient in Sorbs1 gene, which encodes cbl-associated protein (Cap) (19). These mice are also protected from high-fat diet–induced insulin resistance, and this protection can be transferred to wild-type mice by BMT of Cap-null bone marrow. Furthermore, Cap deletion resulted in reduced numbers of monocytes/macrophages in both blood and adipose tissue, and Cap knockdown led to decreased migration in the RAW264.7 macrophage cell line. Previously, Cap was shown to mediate signals for the formation of stress fibers and focal adhesions through interaction with the focal adhesion kinase p125FAK, an effector directly linked to paxillin binding to α4 integrin (15), and Cbl is required for macrophage spreading and migration. Thus, the relationship between Cap and α4-paxillin interaction in the pathogenesis of insulin resistance is an area of potential future interest.

Chronic inflammation can be a primary mediator of obesity-induced insulin resistance, and inflammation is recognized as one of the contributors to the metabolic syndrome (or syndrome X) and type 2 diabetes (46). This study establishes a new role for α4 signaling in the development of high-fat diet–induced insulin resistance through its action on monocyte/macrophage trafficking. It also suggests that blockade of α4 signaling can improve insulin sensitivity and reduce inflammation, which could translate into clinical benefit in type 2 diabetes.

ACKNOWLEDGMENTS
C.C.F. has received a postdoctoral fellowship from the Arthritis Foundation. J.G.N. has received Scientist Development Grant 0635408N from the American Heart Association. C.K. has received a postdoctoral fellowship from the Arthritis Foundation. J.M.O. has received a University of California Discovery Biostar Grant and NIH Grants DK-033651 and DK-074868. M.H.G. has received National Institutes of Health (NIH) Grants AR-27214, HL-078784, and HL-31950.

REFERENCES
1. Golay A, Felber JP: Evolution from obesity to diabetes. Diabete Metab 20:6-14, 1994
2. Rader DJ: Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med 120:S12–S18, 2006
3. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, Karin M: IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 11:191–196, 2005
4. Kanda H, Tateya S, Taniyori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K, Kasuga M: MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116:1494–1505, 2006
5. Rychly J, Nebe B: Therapeutic strategies in autoimmune diseases by interfering with leukocyte endothelium interaction. Curr Pharm Des 12:3799–3806, 2006
6. Kaneider NC, Leger AJ, Kilopulos A: Therapeutic targeting of molecules involved in leukocyte-endothelial cell interactions. FEBS J 273:4416–4424, 2006
7. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnanek P, Zadorova Z, Palmer T, Donoghue S: Natalizumab for active Crohn’s disease. N Engl J Med 348:24–32, 2003
8. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O’Connor PW: A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15–23, 2003
9. Arroyo AG, Yang JT, Rayburn H, Hynes RO: Differential requirements for alpha4 integrins during fetal and adult hematopoiesis. Cell 85:997–1008, 1996
10. Sengbusch JK, He W, Pinco KA, Yang JT: Dual functions of [alpha]4[beta]1 integrin in epicardial development: initial migration and long-term attachment. J Cell Biol 157:873–882, 2002
11. Yang JT, Rayburn H, Hynes RO: Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development. Development 121:549–560, 1995
12. Sheridan C: Tysabri raises alarm bells on drug class. Nat Biotechnol 23:397–398, 2005
13. Sheridan C: Third Tysabri adverse case hits drug class. Nat Rev Drug Discov 4:357–358, 2005
14. Kummer C, Ginsberg MH: New approaches to blockade of alpha4-integrins, proven therapeutic targets in chronic inflammation. Biochem Pharmacol 72:1460–1468, 2006
15. Liu S, Thomas SM, Woodside DG, Rose DM, Kioosses WB, Pfaff M, Ginsberg MH: Binding of paxillin to alpha4 integrins modifies integrin-dependent biological responses. Nature 402:676–681, 1999
16. Alon R, Feigelson SW, Manevitch E, Rose DM, Schmitz J, Overby DR, Winter E, Feigelson V, Shinder V, Matthews BD, Sokolovsky-Eisenberg M, Inger DE, Benoit M, Ginsberg MH: Alpha5beta1-dependent adhesion strengthening under mechanical strain is regulated by paxillin association with the alpha4-cytoplasmic domain. J Cell Biol 171:1073–1084, 2005
17. Rose DM, Liu S, Woodside DG, Han J, Schlaepfer DD, Ginsberg MH: Paxillin binding to the alpha 4 integrin subunit stimulates LFA-1 (integrin alpha L beta 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. J Immunol 170:5912–5918, 2003
18. Feral CC, Rose DM, Liu S, Woodside DG, Han J, Schlaepfer DD, Ginsberg MH: New approaches to blockade of alpha 4 integrins, proven therapeutic targets in chronic inflammation. Biochem Pharmacol 72:1460–1468, 2006
19. Lesniewski LA, Hosch SE, Neels JG, de Luca C, Pashmforoush M, Lumeng CN, Chiang SH, Scadeng M, Saltiel AR, Olefsky JM: Bone marrow-specific Cap gene deletion protects against high-fat diet-induced insulin resistance. Nat Med 13:455–462, 2007
20. Xu W, Hou W, Yao G, Ji Y, Yeh M, Sun B: Inhibition of Th1- and enhancement of Th2-initiating cytokines and chemokines in trichosanthin-treated macrophages. Biochem Biophys Res Commun 294:168–172, 2002
21. Parves RD: Optimum numerical integration methods for estimation of area-under-the-curve (AUC) and area-under-the-moment-curve (AUMC). J Pharmacokinet Biopharm 34:357–358, 2005
22. Bruning JC, Winnay J, Cheatham B, Kahn CR: Differential signaling by insulin receptor substrate 1 (IRS-1) and IRS-2 in IRS-1-deficient cells. Mol Cell Biol 17:1513–1521, 1997
23. Lomb RR, Hemler ME: The pathophysiological role of alpha 4 integrins in vivo. J Clin Invest 94:1722–1728, 1994
24. von Andrian UH, Engelhardt B: Alpha4 integrins as therapeutic targets in chronic inflammation. J Immunol 172:4410–4417, 2004
25. Weisberg SP, Hunter D, Huber R, Leitel AW, Yang JT, Hynes RO: Alpha4 integrins regulate the proliferation/differentiation balance of multilineage hematopoietic progenitors in vivo. Immunity 11:555–566, 1999
26. Weisberg SP, Hunter D, Huber R, Leitel AW, Yang JT, Hynes RO: Alpha4 integrins regulate the proliferation/differentiation balance of multilineage hematopoietic progenitors in vivo. Immunity 11:555–566, 1999
27. Bouloumie A, Curat CA, Sengenes C, Lolmede K, Miranville A, Busse R: Adipose tissue macrophages are independent of neutrophil migration. Diabetes 55:1554–1561, 2006
28. Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A: Inflammatory process in type 2 diabetes: the role of cytokines. Ann N Y Acad Sci 1094:88–97, 2006
29. Chen A, Munick S, Zhang C, Lamb J, Dai H, Weigarth D, Mudgett J, Chen H, MacNeil DJ, Reitman ML, Qian S: Diet induction of monocyte chemoattractant protein-1 and its impact on obesity. Obes Res 13:1311–1320, 2005
30. Jakes R, Madsen O, Kastor L, Jukema JW, Kastelein JJ: Cardiovascular meta-